Tudor

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tudor

Property Description
Active ingredient Venlafaxine hydrochloride
Form Oral capsules (Extended-Release) and tablets (Immediate-Release)
Pharmacological class Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
General purpose Supports neurochemical balance in the central nervous system
Origin Synthetic chemical compound

Tudor: Defining the Drug Entity and Its Class

Tudor is a synthetic psychotropic medication whose active component is Venlafaxine hydrochloride, classified as an antidepressant. The drug specifically belongs to the pharmacological group known as Serotonin-Norepinephrine Reuptake Inhibitors (SNRI). This classification means the medication influences two key signaling molecules in the central nervous system: serotonin and norepinephrine.

This classification is significant because the dual-action mechanism is recognized for its ability to help stabilize neurochemical levels in the brain. This means the medication helps regulate two of the key chemical messengers involved in mood stability, a property associated with its pharmacological profile.

Composition, Origin, and Delivery Forms

The active substance, Venlafaxine hydrochloride, is a single active ingredient product derived from a synthetic chemical compound. This medication is intended for oral ingestion and is available in two primary dosage forms: tablets (typically immediate-release) and capsules (commonly extended-release).

The distinction between the forms relates to the speed of the active ingredient release into the body. While immediate-release tablets release the compound more quickly, the extended-release capsules utilize a specialized pharmaceutical matrix to control the release of the Venlafaxine over a prolonged duration. The long-acting (XR) formulation is a key feature which can enhance the consistency of the drug’s effects.

General Purpose of This Dual-Action Mechanism

The primary, high-level purpose of a medication with this dual-action mechanism is to foster a more balanced and stable neurochemical environment in the brain. This class of medicine is designed to alleviate the effects of neurotransmitter deficits. Consequently, the function of this psychotropic medication is to provide foundational support against imbalances in key neural signaling pathways to aid emotional regulation.

What side effects are possible with Tudor?

The possible side effects and safety characteristics of Tudor (Venlafaxine) are documented in official regulatory sources, including those from the FDA and EMA, and are classified by frequency and the body system affected.

Adverse Reactions by Frequency

Adverse reactions are classified according to incidence observed in clinical use:

  • Very Common (Affecting ge1/10 patients): Nausea, Dry mouth, Headache, Insomnia, and Hyperhidrosis (sweating, including night sweats).
  • Common (Affecting ge1/100 to <1/10 patients): Dizziness, Somnolence (drowsiness), Constipation, Vomiting, Hypertension, Tachycardia, and sexual dysfunction (e.g., decreased libido, abnormal ejaculation).
  • Rare (Affecting <1/1,000 patients): Reported serious events include Serotonin Syndrome, Seizures, and Angle-Closure Glaucoma.

Serious Adverse Reactions and Warnings

The FDA label includes a Boxed Warning regarding the increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults (up to age 24), particularly during the initial period of treatment. Other documented serious risks include sustained Elevated Blood Pressure, increased risk of Abnormal Bleeding (including gastrointestinal haemorrhage), and Neuroleptic Malignant Syndrome (NMS)-like reactions.

Population-Specific Constraints

Regulatory documentation defines specific constraints for certain patient groups: Tudor is not approved for use in pediatric patients (under 18). Furthermore, dose reduction is recommended for individuals with hepatic (liver) impairment and renal (kidney) impairment, as clearance of the drug and its active metabolite is significantly altered in these patients. Abrupt discontinuation may lead to symptoms, necessitating a gradual dose reduction as stated in regulatory documents.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents for Tudor (Venlafaxine) strictly define the overdose profile by specific clinical manifestations and mandatory emergency actions, ensuring a focus on critical risks and necessary management.

Domain Documented Manifestations and Risks
Clinical Presentation Overexposure may manifest with central nervous system effects such as somnolence, mydriasis, and seizures (convulsions). Other documented signs include tachycardia (rapid heart rate), hypotension (low blood pressure), and gastrointestinal disturbances like nausea and vomiting.
Severe Outcomes Life-threatening risks include the development of potentially fatal conditions such as Serotonin Syndrome, progression to coma, and severe cardiovascular toxicity. This toxicity includes documented risks of QRS/QT prolongation and serious ventricular dysrhythmias. Regulatory data notes an increased risk of fatal outcomes compared to some other antidepressant classes.
Emergency Action Immediate medical attention must be sought for any suspected overexposure. Emergency services must be contacted immediately if the individual collapses, has a seizure, or cannot be awakened. No specific antidote is known for Venlafaxine.

Management of overdosage is strictly symptomatic and supportive. Procedural steps, which may include the administration of activated charcoal or gastric lavage, are guided by standard medical protocols, while official labeling notes that hemodialysis is unlikely to be beneficial. Due to the risk of cardiotoxicity, continuous cardiac rhythm monitoring is required, and extended observation may be necessary, particularly following ingestion of the Extended-Release formulation due to the potential for delayed toxicity.

Therapeutic Uses of Tudor

What Tudor Treats: Main Uses and Benefits

Tudor (Venlafaxine) is commonly used across therapeutic domains to provide symptomatic relief in conditions characterized by significant disturbances in mood and anxiety levels. The medication's application in these therapeutic domains focuses on specific clinical manifestations.

Managing Core Depressive States and Low Energy

This medication is commonly used to help with Major Depressive Disorder (MDD), addressing the core cluster of symptoms that includes persistent low mood, anhedonia (loss of interest), and associated fatigue. It provides supportive therapeutic benefit by helping to ease emotional tension and reduce the overall symptom burden that interferes with motivation and daily functioning.

Relieving Chronic Excessive Worry and Tension

Tudor is generally relevant in clinical settings marked by Generalized Anxiety Disorder (GAD), where patients experience chronic, intense worry and persistent physical and mental tension. The treatment is applied to ease these challenging, distressing manifestations, assisting with general well-being during symptomatic phases. It is also used across anxiety domains that feature acute fear responses, such as Panic Disorder and Social Anxiety Disorder.


Quick Fact: Relief for Chronic Excessive Worry Tudor is considered relevant for managing the persistent, physical and mental tension and apprehension associated with Generalized Anxiety Disorder (GAD).


Regulatory References

  1. NIH MedlinePlus overview of Venlafaxine

Eligibility and Restrictions for Use

The eligibility for using Tudor (Venlafaxine) is strictly defined by regulatory authorities based on population and clinical status.

Eligibility Scope

Category Regulatory Status
Approved Age Group Adults (18 years and older) are the approved population.
Pediatric Use Not approved for use in children and adolescents (under 18); use is generally not established or recommended.

Absolute Non-Eligibility

Tudor is contraindicated (must not be used) in patients with a known hypersensitivity to venlafaxine or any components of the formulation. It is also contraindicated for use in combination with a Monoamine Oxidase Inhibitor (MAOI), or within 14 days of stopping an MAOI. A seven-day washout period is required after stopping Tudor before an MAOI may be started.

Conditional Use and Restrictions

Eligibility is conditional for patients with significant organ impairment, as defined by regulators. Those with renal impairment or hepatic impairment require cautious use due to altered drug clearance. Furthermore, caution and pre-screening are mandated for patients with untreated hypertension, a history of seizures, or a risk of bipolar disorder/mania.

Pregnancy and Lactation

Use during pregnancy (especially the third trimester) is generally considered only if clearly needed. The drug is excreted into human milk, and the official labeling requires a careful assessment of the benefits to the mother against the potential for adverse reactions in the infant, often necessitating the discontinuation of nursing or the medicine.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Tudor (Venlafaxine) into categories defining risk and constraints. Co-administration with Monoamine Oxidase Inhibitors (MAOIs), including Linezolid and Intravenous Methylene Blue, is strictly contraindicated due to the high risk of a serious pharmacodynamic interaction known as Serotonin Syndrome. A mandatory 14-day washout period is required after stopping an MAOI before initiating Tudor, and a 7-day washout is required after stopping Tudor before starting an MAOI.

Pharmacokinetic and Pharmacodynamic Interactions

The medication is a weak inhibitor of CYP2D6, which is documented as leading to a pharmacokinetic interaction that increases the plasma exposure of co-administered CYP2D6 substrates such as Metoprolol and Haloperidol. Conversely, strong CYP3A4 inhibitors (e.g., Ketoconazole) are noted to increase the exposure (AUC and C max) of Venlafaxine and its active metabolite. Combining Tudor with other serotonergic drugs (e.g., Triptans, SSRIs, Tramadol) carries an additive risk of Serotonin Syndrome.

Official prescribing information also addresses hemostasis interference: co-administration with NSAIDs (e.g., Aspirin) or anticoagulants (e.g., Warfarin) is documented as increasing the risk of bleeding. Furthermore, consumption of alcohol with the extended-release formulation is not recommended as in vitro data indicates a potential to accelerate the release of the active ingredient. In patients with documented Hepatic Impairment, reduced clearance officially results in increased exposure to the active compounds.

Mechanism of Action

Epigenetic Regulation via Methylation Sensing

This domain focuses on Tudor's function as an epigenetic reader, specifically recognizing and binding to methylated amino acid residues (like methylated lysine and arginine) on histone and non-histone proteins. This mechanism influences chromatin structure and transcriptional control, influencing transcription of genes associated with cellular growth, stress response, and differentiation.


Modulation of DNA Damage and Repair Mechanisms

Tudor engages with proteins in the DNA damage response (DDR) pathway, acting as an adaptor to sense DNA damage and recruit effector proteins to the site of injury. This interaction regulates the cell cycle and processes involved in genome integrity, contributing to modulating cell cycle progression and affecting cellular fate pathways.


RNA Metabolism and Cellular Assembly

This domain involves Tudor's role in RNA binding and the assembly of key cellular machinery, such as components of the spliceosome. By mediating specific protein-protein and protein-RNA interactions, Tudor mediates the processing and trafficking of RNA transcripts, influencing the resulting output of cellular proteins and pathway activity.

Dosage and Administration Information

Administration Guidelines for Tudor (Venlafaxine)

This section describes the high-level instructions for how Tudor (Venlafaxine) is administered, specifically for the extended-release (XR) formulation.


Dosing Schedule and Frequency

Administration of the extended-release form is once daily, and the medication must be taken at the same time each day, either in the morning or evening. For most adult patients, the recommended starting daily dose is 75 mg. However, a dose of 37.5 mg per day may be used for the first 4 to 7 days before increasing to 75 mg.

Doses are typically increased in increments of up to 75 mg per day, with adjustments occurring at intervals of not less than four days. The typical adult maintenance range is between 75 mg and 225 mg per day. While some regions approve a maximum dose of 375 mg/day for the immediate-release form in severe cases, the maximum daily dose for the extended-release form is generally 225 mg.


Intake Conditions and Restrictions

All forms of Venlafaxine must be taken with food to ensure proper conditions for absorption. Extended-release capsules or tablets must be swallowed whole with fluid and are not to be divided, crushed, chewed, or dissolved, as this would compromise the controlled release mechanism. For patients who cannot swallow the capsule whole, the contents may be carefully sprinkled onto a spoonful of applesauce and swallowed immediately without chewing.


Procedural Use Over Time

Discontinuation of the medicine must be achieved through a gradual dose tapering process, not by abrupt cessation. The dose should be reduced slowly, such as by 75 mg at weekly intervals, with the tapering schedule individualized to the patient's response.

Population-Specific Adjustments: Reductions in the total daily dose are required for patients with impaired organ function. A dose reduction of 25% to 50% or more is necessary for patients with severe renal impairment, and a dose reduction of at least 50% is generally required for patients with mild to moderate hepatic impairment.

Recent Clinical Evidence

Research evidence / Overview of studies for Tudor (Venlafaxine)

This section provides an overview of the types of official research that have been conducted on Venlafaxine (Tudor), focusing on the study designs, the outcomes that were measured, and the research uncertainties noted in scientific literature. It does not offer clinical advice or describe expected personal outcomes.


Evidence for use in Major Depressive Disorder (MDD)

Research on the use of Tudor for MDD includes multiple short-term, randomized, double-blind, placebo-controlled trials (RCTs). These studies typically monitored adult outpatients and were used to explore how symptoms change over time, measuring outcomes using validated rating scales like the HAM-D and MADRS.

What the studies reported: Findings describe patterns observed in the studies regarding symptom evolution compared to placebo, with research highlighting changes measured during the study period related to core symptoms like persistent low mood and low energy. Long-term maintenance studies monitored the cumulative probability of recurrence of major depression over observation periods of 12 months or more, with findings describing the patterns observed in the measured group outcomes.


Evidence for Anxiety Disorders

The evidence base for Generalized Anxiety Disorder (GAD) also includes multiple placebo-controlled RCTs, focusing on both the psychic (worry, apprehension) and somatic (physical tension, restlessness) anxiety factors. Long-term studies were conducted to evaluate the persistence of the measured outcomes over half a year.

Research for Social Anxiety Disorder (SAD) and Panic Disorder (PD) also involves controlled trials. For PD, the primary focus was on monitoring the frequency of full-symptom panic attacks. For SAD, research primarily examined outcomes related to daily functioning using scales like the Liebowitz Social Anxiety Scale (LSAS). The core evidence for Panic Disorder and Social Anxiety Disorder is often categorized as Moderate in the research literature.


Key Limitations and Areas of Research Uncertainty

The research provides insight into short-term changes, but several limitations are noted:

  • Applicability: The results apply primarily to the specific populations studied, as many trials excluded individuals with complicated clinical presentations or certain co-occurring conditions.
  • Long-Term Outcomes: While maintenance data exists from studies monitoring recurrence in MDD and relapse in GAD, the research does not characterize outcomes for treatment durations exceeding two years.
  • Comparative Data: For several indications, comparative evidence is lacking against the full range of currently available treatment options.

Research is ongoing to better understand these outcomes, but patients should understand that findings describe group patterns, not personal outcomes or guarantees of lasting relief.

Frequently Asked Questions (FAQ)

Common questions about Tudor (FAQ)


Q: What is the main reason doctors prescribe Tudor?

The official indications for this medication are the treatment of Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD) in adult patients. Some authoritative sources also list its use for Panic Disorder and Social Anxiety Disorder. These conditions represent the primary purposes for which the drug is prescribed by healthcare providers.


Q: Does Tudor cause weight gain or loss?

Regulatory documents indicate that weight loss has been reported as an adverse effect in clinical studies. Loss of appetite, known as anorexia, is also listed as a common adverse reaction in official product information. Discussing any significant or concerning weight changes with a healthcare provider may be advisable.


Q: Is it normal to feel a change in appetite when starting Tudor?

A change in appetite, specifically a decrease in appetite (anorexia), is described in official product information as a common adverse reaction. Any substantial or bothersome change in eating habits is something to consider discussing with a healthcare professional.


Q: How long does it usually take for Tudor to start working?

Clinical studies for the approved uses of the medication typically run for several weeks. Authoritative sources suggest that it can take four to six weeks for patients to experience the full, intended effect of the medication. Consistency in taking the medication is generally considered important throughout this period.


Q: What happens if I forget to take Tudor for one day?

Official guidance indicates that a missed dose may be taken as soon as it is remembered, unless it is nearly time for the next scheduled dose. It is crucial to remember that doses should never be doubled to make up for a forgotten dose. Consistency in taking the medication is key to its intended effect.


Q: Are there any common foods or drinks that interact with Tudor?

Official instructions require that the extended-release form of the medication be taken with food to ensure proper absorption conditions. Consumption of alcohol is generally not recommended because in vitro data indicates a potential for the alcohol to accelerate the drug's release. No other common foods or drinks are specifically listed in the regulatory documents as carrying a known risk of interaction.


Q: Does Tudor interact with blood pressure medication?

According to official warnings, the medication may cause elevations in blood pressure, necessitating regular monitoring during treatment. Furthermore, the drug can interact with blood pressure medicines like Metoprolol by affecting their concentration in the body. The control of hypertension is a factor generally considered necessary prior to initiating this treatment.


Q: Can older people use Tudor?

The medication is approved for use in adults, which includes the older population. However, regulatory documents advise caution in geriatric patients. Older adults may have a heightened risk of developing hyponatremia (low sodium levels in the blood), so monitoring may be necessary during treatment.


Q: Is there any research evidence on how Tudor affects sleep?

According to the official adverse reaction data, the medication does affect sleep. Insomnia (trouble sleeping) is listed as a Very Common side effect, and somnolence (drowsiness) is a Common side effect. This information describes patterns observed in clinical use.


Q: Why is Tudor sometimes used by people who don't have the main condition it treats?

The use of the drug for conditions other than those formally approved by regulators is called off-label use. Authoritative sources, such as the National Institutes of Health (NIH), note that the drug is commonly used off-label for certain types of chronic pain, hot flashes, and anxiety beyond the approved generalized anxiety disorder.


Q: Is Tudor addictive?

The medication is not classified as a controlled substance under the Controlled Substances Act (CSA) and is not associated with a pattern of abuse. However, regulatory documents note that abruptly stopping the medicine can lead to a discontinuation syndrome (withdrawal symptoms). This is a known biological effect that is distinct from addiction.


Q: Does taking Tudor mean I have to stop drinking alcohol completely?

Official patient counseling advises against the consumption of alcohol while taking the extended-release formulation. This is because laboratory data suggests alcohol may accelerate the release of the active ingredient into the body. Alcohol may also worsen potential central nervous system side effects like dizziness or drowsiness.


Q: Is Tudor considered a controlled substance?

According to official regulatory records, the medication is not listed as a controlled substance. This means it is not subject to the specific prescribing and record-keeping regulations that apply to scheduled drugs.


Q: Does Tudor interact with common over-the-counter cold medicines?

Official drug interaction information warns against co-administering the drug with other serotonergic agents. Some common over-the-counter cold and cough remedies contain ingredients that affect serotonin, creating a potential risk for interaction. It is important for patients to discuss all medications and non-prescription products with a healthcare provider before initiating this treatment.


Q: Is there a generic version of Tudor available?

Yes, the active ingredient in this medication is Venlafaxine hydrochloride. This generic form is widely available and approved by regulatory bodies to be used in place of the brand-name product.


Q: Is Tudor known to cause mental fog or concentration issues?

Official warnings indicate that common side effects, including dizziness and somnolence (drowsiness), may affect a person's judgment, thinking, and motor skills. This effect could potentially be perceived as mental fog or concentration difficulty. Patients are cautioned to understand how the medication affects them before driving or operating machinery.


Q: What is the experience of people who have been on Tudor for over a year?

Research studies have examined the continued use of this medication for extended periods, including long-term maintenance trials that lasted up to 12 months or more. These studies tracked group outcomes related to the prevention of symptom recurrence in patients with Major Depressive Disorder. Official findings describe group patterns, not personal results or guarantees of outcomes.


Q: Can I take Tudor if I use herbal supplements?

Official patient information specifically warns against taking the medication with the herbal supplement St John’s wort. Co-administration is advised against because it can increase the risk of a serious reaction called Serotonin Syndrome. Reviewing all supplements, including herbal ones, with a healthcare provider prior to use is important.


Q: Does Tudor affect blood sugar levels?

While not a direct contraindication, authoritative patient information recommends that individuals with diabetes monitor their blood sugar more closely than usual, especially when beginning treatment. This cautious approach helps to identify any potential changes early in therapy.


Q: Is it true that Tudor has been studied for other uses?

It is a known fact that the drug's active component has been researched for uses other than its main regulatory approvals. Authoritative sources, such as the NIH, note that it is commonly used off-label for conditions like certain chronic pain states and the management of hot flashes.


Q: Is there a common reason why doctors might switch a patient from Tudor to another drug?

While the decision to switch drugs is a clinical one, literature indicates that patients sometimes stop using the medicine due to certain adverse effects. Significant side effects such as sexual dysfunction and persistent issues like fatigue are often cited as reasons for treatment noncompliance in research.


Q: Does Tudor have a known withdrawal period when stopping treatment?

Official warnings describe a known Discontinuation Syndrome (or withdrawal period) that can occur if the medicine is stopped abruptly. Therefore, the dose must be reduced gradually over time under the direction of a healthcare provider, and the patient must be monitored throughout this process.


Q: What is the maximum duration of use that has been studied in clinical trials?

Research has established the efficacy of the drug in long-term maintenance studies that have lasted up to 12 months for conditions such as Major Depressive Disorder. These studies describe observed outcomes in groups of patients treated over this duration.


Q: Is Tudor a medication that needs to be taken long-term?

The medication is approved for the long-term treatment (maintenance) of its approved conditions, such as Major Depressive Disorder and Generalized Anxiety Disorder. Decisions regarding the duration of use are based on individual patient need and are made by a healthcare provider.


Q: Can I drive while taking Tudor?

Because common side effects include dizziness and drowsiness (somnolence), the medication can impair thinking and motor skills. Official patient counseling generally recommends that individuals understand how the drug affects them personally before driving or operating dangerous machinery.


Q: What happens if I accidentally take two doses of Tudor close together?

Regulatory information warns that an overdosage of the medication can be serious. Patients are explicitly advised never to double a dose to compensate for a missed one. If an overdose is suspected, seeking immediate emergency medical care is necessary.


Q: Why do people sometimes stop taking Tudor?

Research and literature indicate that patients sometimes stop taking the medication due to persistent or bothersome adverse effects. Significant side effects, such as sexual dysfunction, are frequently cited as reasons for a patient's decision to discontinue the medication.


Q: What kind of feelings are associated with the dual-action mechanism of Tudor (SNRI)?

This medication is classified as a Serotonin-Norepinephrine Reuptake Inhibitor (SNRI), meaning it influences two key brain chemicals. These chemicals, serotonin and norepinephrine, are neurotransmitters linked to the regulation of mood, energy, and alertness. The intended effect is to support emotional regulation and balance neurochemical levels.


Q: Can I have sexual side effects from Tudor even after stopping it?

For most people, sexual side effects that occurred during treatment typically resolve or improve once the medication is stopped. However, authoritative sources note that there have been rare reports of sexual dysfunction persisting in patients even after the drug has been discontinued.


Q: Can Tudor cause liver problems?

The medication is processed by the liver, and official labeling indicates that patients with existing hepatic impairment (liver issues) may require a dose adjustment. This is necessary because the liver's ability to clear the drug and its active components may be altered.


Q: What are the early signs of a severe allergic reaction to Tudor?

Regulatory documents establish that the drug is contraindicated (must not be used) in anyone with a known hypersensitivity or allergy to the drug or its components. Signs of a severe allergic reaction typically involve difficulty breathing, swelling, or rash. Seeking immediate medical attention is necessary should these signs appear.


Q: Are there any risks if I have a history of seizures and take Tudor?

Official warnings note that the medication can cause seizures in some patients. For this reason, it is required to be used with caution in patients who have a pre-existing history of a seizure disorder. The assessment of this risk is typically done by a healthcare provider.


Q: Is it safe to switch from another antidepressant to Tudor immediately?

When switching from a Monoamine Oxidase Inhibitor (MAOI), a mandatory 14-day washout period is required before starting this medication. For all other antidepressants, switching should be done under the direction of a healthcare provider with careful monitoring, as abrupt transitions can lead to adverse effects.


Q: Can Tudor increase my cholesterol?

Clinical trial data indicates that clinically relevant increases in serum cholesterol levels were reported in a percentage of patients using the medication for long periods (at least three months). Therefore, regulatory information suggests that the measurement of cholesterol levels should be considered during long-term treatment.

How should Tudor be stored and disposed of?

How to Store and Dispose of Tudor (Venlafaxine)

Tudor (Venlafaxine) must be stored according to official regulatory requirements to maintain product stability and safety. The product should be kept at Controlled Room Temperature, which is 20 C to 25 C (68 F to 77 F), with permitted short excursions up to 30 C (86 F). The medicine must be kept in its original container and be tightly closed to protect it from moisture. It should not be stored in the bathroom.

Disposal Requirements

To dispose of unused or expired Tudor, use a drug take-back program. If this option is unavailable, the medicine should be mixed with an undesirable substance, such as dirt or used coffee grounds, placed in a sealed container, and then discarded in the household trash. The medication must be secured out of the sight and reach of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tudor found in:

A-Z Index: